Combinib 250 mg TabletsGeneric Name: Lapatinib Brand Name: Combinib 250 mg Strength: 250 mg Manufacturer: Cipla Ltd. Form: Tablet Dosage Form: Oral Packaging Type: Bottle / Blister / Strip Packaging Size: 30 Tablets per Bottle Prescription Required: Yes Country of Origin: Made in India Minimum Order Quantity: 1 Bottle Storage Conditions: Store at room temperature Weight per Bottle: Approx. 250 gm Expiry: Long Shelf LifeComposition: Active Ingredient: Lapatinib Ditosylate Equivalent to Lapatinib 250 mg Therapeutic Indication:Combinib is indicated for the treatment of: Metastatic Breast Cancer (HER2-positive), often in combination with other therapies such as capecitabine or letrozole. Mechanism of Action:Lapatinib is a dual tyrosine kinase inhibitor that blocks two specific enzymes (EGFR and HER2/neu receptors) responsible for the growth and survival of cancer cells. It is especially effective in HER2-positive breast cancer cases.International Brand Equivalent: Tykerb® 250 mg by Novartis Dosage & Administration: To be taken exactly as directed by an oncologist Typically taken on an empty stomach, at least 1 hour before or after meals Must be used in conjunction with other prescribed cancer treatments Key Features: Manufactured by Cipla, a globally trusted pharmaceutical company Cost-effective alternative to international brands Supplied in a convenient 30-tablet bottle Suitable for clinical use and global oncology distribution Ideal for drop shipping and export markets due to stable shelf life and durable packaging
